Pityriasis Rosea - StatPearls - NCBI Bookshelf PDF
Pityriasis Rosea - StatPearls - NCBI Bookshelf PDF
Pityriasis Rosea - StatPearls - NCBI Bookshelf PDF
Introduction
Pityriasis rosea is an acute self-limiting papulosquamous disorder. It is characterized by a herald patch followed by scaly oval
patches on the trunk and proximal extremities in a "Christmas-tree" appearance. Pityriasis rosea means rose-colored scale.
Pityriasis rosea is also known as pityriasis circinata, roseola annulata, and herpes tonsurans maculosus. The skin eruption
usually lasts 6-8 weeks and begins with a 'herald patch.' [1][2][3]
Etiology
The exact cause of pityriasis rosea is not known, but features like seasonal variation and clustering in communities suggest
that it is an infectious disease. Infections like viruses, bacteria, spirochetes, and noninfective causes like atopy and
autoimmunity are known causes. Upper respiratory tract infections that precede pityriasis rosea suggest a role of
Streptococcus. Recently, reactivation of latent human herpesvirus-6 and human herpesvirus-7 infection have been found as the
possible etiologic agents. Pityriasis rosea-like eruptions have been reported after vaccinations such as Bacillus Calmette-
Guerin, influenza, H1N1, diphtheria, smallpox, hepatitis B, and Pneumococcus. Eruptions have also been seen with drugs like
gold, captopril, barbiturates, D-penicillamine, and clonidine. In temperate regions, it is more common in the winter season,
while in tropical areas some seasonal variation is noted.[4][5][6]
Epidemiology
The approximate incidence of pityriasis rosea is 0.5% to 2%. It affects people of both genders between 15 and 30 years of age,
but it also affects older adults and children.[7]
Pathophysiology
A lack of natural killer (NK) cell and B-cell activity in pityriasis rosea lesions has been noted, suggesting a predominantly T-
cell mediated immunity. Increased amounts of CD4 T-cells and Langerhans cells are present in the dermis, possibly reflecting
viral antigen processing and presentation. Anti-immunoglobulin M (IgM) keratinocytes have been found in patients with
pityriasis rosea. This may be associated with the exanthem phase of viral infection.
Histopathology
Skin biopsy is not necessary but if performed will reveal non-specific features similar to those seen in chronic dermatitis.
Pruritus is severe in 25% of cases. Herald patch is seen in 50% to 90% cases and is located on the trunk followed by the neck
or proximal extremity.
A generalized eruption then occurs, in which numerous lesions develop in crops over a period of one to two weeks after the
onset of the herald patch. The eruptions are symmetric and most commonly involve the thorax, back, abdomen, and adjoining
areas of the neck and extremities. These secondary lesions occur as macules and papules that are elliptical or ovular in shape.
The incidence of atypical pityriasis rosea is 20% which maybe regard morphology, size, distribution, course, or symptoms.
The rashes of pityriasis rosea usually last for five weeks and resolve by 8 weeks in more than 80% of patients. Pityriasis rosea
needs to be differentiated from secondary syphilis, dermatophytosis, guttate psoriasis, nummular eczema, pityriasis lichenoid
chronic, cutaneous T-cell lymphoma, erythema annular centrifugal and erythema chronic migrans.
Evaluation
Histopathology shows superficial perivascular dermatitis. Focal parakeratosis in mounds, hyperplasia, and focal spongiosis are
observed in the epidermis. The epidermis may show exocytosis of lymphocytes, variable spongiosis, mild acanthosis, and a
thinned granular layer. Extravasated red blood cells along with a perivascular infiltrate of lymphocytes, histiocytes, and
eosinophils are seen in the dermis.[2][8][9]
Treatment / Management
Pityriasis rosea is a self-limiting, exanthematous disease. Most patients need emollients, antihistaminics, and topical steroids.
Macrolides and acyclovir lead to faster resolution of lesions and help to relieve pruritus. Narrowband ultraviolet B therapy is
also used. It works by altering the immunology in the skin.[10]
Questions
To access free multiple choice questions on this topic, click here.
Figure
Pityriasis Rosea. Contributed by DermNetNZ
References
1. Drago F, Ciccarese G, Parodi A. Pityriasis rosea and pityriasis rosea-like eruptions: How to distinguish them? JAAD Case
Rep. 2018 Sep;4(8):800-801. [PMC free article: PMC6142012] [PubMed: 30246131]
2. Trayes KP, Savage K, Studdiford JS. Annular Lesions: Diagnosis and Treatment. Am Fam Physician. 2018 Sep
01;98(5):283-291. [PubMed: 30216021]
3. Chang HC, Sung CW, Lin MH. The efficacy of oral acyclovir during early course of pityriasis rosea: a systematic review
and meta-analysis. J Dermatolog Treat. 2019 May;30(3):288-293. [PubMed: 30109959]
Publication Details
Author Information
Authors
A!liations
1 Desert Regional Medical Center
Publication History
Copyright
Copyright © 2020, StatPearls Publishing LLC.
This book is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/),
which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original
author(s) and the source, a link is provided to the Creative Commons license, and any changes made are indicated.
Publisher
NLM Citation
Litchman G, Nair PA, Le JK. Pityriasis Rosea. [Updated 2019 Jun 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-.